Doctors say PCSK9 inhibitor use should be limited
Leading physicians said the use of newly FDA-approved proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors should be limited to a small number of patients who cannot tolerate statins.
The doctors spoke at a "Rethinking Cholesterol" panel presented by Harvard T.H. Chan School of Public Health in collaboration with Reuters.
This summer, the FDA approved alirocumab (Praluent, Regeneron Pharmaceuticals and Sanofi Aventis) and evolocumab (Repatha, Amgen) as an adjunct to diet and exercise to lower low-density lipoprotein cholesterol.
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.